Haematology Clinical Guidelines
Multiple myeloma, lymphoma, and haematological malignancy treatment algorithms — disease-specific, trial-evidence backed, and integrated with clinical calculators.
Clinical Guideline Sections
Select a disease to access the full treatment algorithm, trial data, and decision trees.
Multiple Myeloma
Multiple myeloma from diagnosis to transplant — CRAB criteria, ISS/R-ISS/R2-ISS risk stratification, induction with Dara-VTd/Dara-VRd, ASCT workflow, maintenance, and R/R sequencing including bispecifics and CAR-T.
- Diagnosis & Workup (CRAB, M-protein)
- Risk Stratification (ISS, R-ISS, R2-ISS)
- 1L Treatment & ASCT
- Complications (Renal, TLS)
- R/R MM & Novel Therapies
Primary CNS Lymphoma (PCNSL)
PCNSL management — HDMTX-based induction (R-MPV, MATRix), response assessment with RANO-PCNSL, consolidation with ASCT vs WBRT, and salvage strategies including TEDDI-R and ibrutinib.
- Induction (HDMTX, R-MPV, MATRix)
- Consolidation (ASCT vs WBRT)
- Salvage (TEDDI-R, Ibrutinib)
- Ocular Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
DLBCL clinical notes — R-CHOP, risk stratification by IPI and COO, CNS prophylaxis, and management of transformed disease.
- Risk Stratification (IPI, COO)
- 1L Treatment (R-CHOP, Pola-R-CHP)
- R/R DLBCL & CAR-T
Follicular Lymphoma (FL)
Follicular lymphoma — watch and wait criteria, first-line rituximab-based chemoimmunotherapy, transformation risk, and novel therapies.
- Grading & Pathobiology
- Watch and Wait
- 1L Chemoimmunotherapy
Hodgkin Lymphoma (HL)
Classic Hodgkin lymphoma — early favourable and unfavourable, advanced stage ABVD and BrECADD, PET-adapted strategies, and R/R including brentuximab vedotin and checkpoint inhibitors.
- Early-Stage HL
- Advanced HL (ABVD, BrECADD)
- R/R HL
Clinical reference only. These guidelines are intended to support, not replace, clinical judgment. Treatment decisions should be individualised based on patient-specific factors, local protocols, and multidisciplinary team input. Always apply clinical judgment and consult local institutional guidelines where applicable.